Dr Arvindran A/L Alaga
1 clinical trials · Sponsor
◉ Watch Dr Arvindran A/L Alaga
| Record | Firm | Date |
|---|---|---|
| Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC (NCT07050043) | Dr Arvindran A/L Alaga | 2025-05-19 |
Track Dr Arvindran A/L Alaga automatically
Every clearance here is in the API, with alerts when new ones post.